title: Clinical experience with biphasic insulin aspart in people with type 2 diabetes: Results from the Libya cohort of the A1chieve study.
abstract: BACKGROUND
  The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents.
  
  
  METHODS
  Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled in biphasic insulin aspart sub group from Libya.
  
  
  RESULTS
  A total of 179 patients were enrolled in the biphasic insulin aspart subgroup. All the patients were prior insulin users. At baseline glycaemic control was poor (mean HbA1c: 9.3%). After 24 weeks of treatment there was an improvement in HbA1c (-0.9%). Hypoglycaemic events reduced from 7.2 events/patient-year to 3.7 events/patient-year in 24 weeks. SADRs did not occur in any of the study patients.
  
  
  CONCLUSIONS
  Starting or switching to biphasic insulin aspart was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
authors.affiliation: Diabetic Centre, Benghazi, Libya.
authors.forename: Issam M
authors.initials: IM
authors.lastname: Hajjaji
authors.affiliation: Alafia Clinic, Benghazi, Libya.
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Sherif
authors.affiliation: Tripoli Medical Centre, Benghazi, Libya.
authors.forename: Aisha
authors.initials: A
authors.lastname: Elazrag
authors.affiliation: Benghazi-Libya.
authors.forename: Suhair
authors.initials: S
authors.lastname: Jaber
authors.affiliation: Department of CMR Novo Nordisk Pharma Gulf FZ-LLC, Dubai, UAE.
authors.forename: Praful N
authors.initials: PN
authors.lastname: Chakkarwar
authors.affiliation: Department of Endocrinology Division and Medicine, Benghazi Medical Treatment, Benghazi, Libya.
authors.forename: Salem
authors.initials: S
authors.lastname: Eltabal
keywords: A1chieve study; Libya; biphasic insulin aspart; type 2 diabetes mellitus